Comparative assessment of ACE inhibitors: What differences are relevant?;Vergleichende evaluation der ACE-hemmer: Welche unterschiede sind relevant?

Schweizerische Medizinische Wochenschrift

Volumn 129, Issue 29-30, 1999, Pages 1053-1060

  Fischler, M P ^a   Follath, F ^a  

^a Medizinische Klinik Zurich   (Switzerland)

Author keywords

ACE inhibitors; Adverse effects; Heart failure; Hypertension; Nephropathy; Pharmacokinetics; Renal failure

Indexed keywords

BENAZEPRIL; CAPTOPRIL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FOSINOPRIL; LISINOPRIL; RAMIPRIL; SPIRAPRIL; TRANDOLAPRIL;

ANGIONEUROTIC EDEMA; BIOAVAILABILITY; BONE MARROW SUPPRESSION; CONTROLLED STUDY; COUGHING; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; FETUS DISEASE; HEART FAILURE; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; KIDNEY FAILURE; LIVER FAILURE; PREGNANCY; PROTEINURIA; REVIEW;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CLINICAL TRIALS; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; PREGNANCY;

EID: 0033609540     PISSN: 00367672     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Vaughan DE. Endothelial function, fibrinolysis, and angiotensin-converting enzyme inhibition. Clin Cardiol 1997;20 (11 Suppl 2):II-34-7.
2. Berne C. Metabolic effects of ACE inhibitors. J Intern Med 1991;229(Suppl 2):119-25.
3. Leonetti G, Cuspidi C. Choosing the right ACF. inhibitor. Drugs 1995;49:516-35.
4. Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential Hypertension. JAMA 1996;275:1507-13.
5. Swales JD. Pharmacological treatment of hypertension. Lancet 1994;344:380-5.
6. Tomlinson B. Optimal dosage of ACE inhibitors in older patients. Drugs & Aging 1996;9:262-73.
7. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in congestive heart failure. N Engl J Med 1987; 316:1429-35.
8. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
9. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992;327:669-77.
10. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;325:293-302.
11. The CONSENSUS II Trial Study Group. Effect of the early administration of enalapril on mortality in patients with acute myocardial infarction. N Engl J Med 1992;327: 678-84.
12. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-8.
13. Gruppo Italiano per lo Studio della Sopravivenza nell'infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate single and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343:1115-22.
14. ISIS-4 Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58050 patients with suspected acute myocardial infarction. Lancet 1995;345: 669-85.
15. Köber L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lynborg K, et al. TRACE Study Group. A clinical trial of the angiotensin-converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995;333:1670-6.
16. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-62.
17. The GISEN Group. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997;349:1863-75.
18. Remuzzi G, Ruggenenti P, Mosconi L, Pata VV. Effect of low-dose enalapril on glomerular size selectivity in human diabetic nephropathy. J Nephrol 1993;6:36-43.
19. EUCLID Study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997;349:1787-92.
20. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998;338:645-52.
21. Tatti P, Pahor M, Byington RP, Di Mauro P, Guarisco R, Strollo G, et al. Outcome results of the fosinopril versus amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998;21:597-603.
22. Reid JL. ACE inhibitors: future perspectives. J Cardiovasc Pharmacol 1993;22:S41-S43.
23. Wellstein A, Essig J, Belz GG. Inhibition on angiotensin I response by cilazapril and its time course in normal volunteers. Clin Pharmacol Ther 1987;41:639-44.
24. Hoyer J, Schulte KL, Lenz T. Clinical pharmacokinetics of angiotensin-converting enzyme (ace) inhibitors in renal failure. Clin Phamacokinet 1993;24:230-54.
25. Ohnishi A, Tsuboi Y, Ishizaki T, Kubota K, Ohno T, Yoshida H, et al. Kinetics and dynamics of enalapril in patients with liver cirrhosis. Clin Phamacol Ther 1989;45:657-65.
26. Dzau VJ. Renal effects of angiotensin-converting enzyme inhibition in cardiac failure. Am J Kidney Dis 1987;10:74-80.
27. Ljungman S, Kjekshus J, Swedberg K. CONSENSUS Trial Group. Renal function in severe congestive heart failure during treatment with enalapril (the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS] Trial). Am J Cardiol 1992;70:479-87.
28. The RALES Investigators. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (The Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol 1996;78:902-7.
29. Hricik DE, Browing PJ, Kopelman R, Goorno WE, Madias NF, Dzau VJ. Captopril-induced functional renal insufficiency in patients with bilateral renal-artery stenoses or renal-artery stenosis in a solitary kidney. N Engl J Med 1983; 308:373-6.
30. Slater EF, Merrill DD, Guess HA, Roylance PJ, Cooper WD, Inman WH, et al. Clinical profile of angioedema associated with angiotensin-converting enzyme inhibition. JAMA 1988;260:967-70.
31. Sedman AB, Kershaw DB, Bunchman TE. Recognition and management of angiotensin-converting enzyme inhibitor fetopathy. Pediatr Nephrol 1995;9:382-5.
32. Pryde PG, Sedman SB, Nugent CE, Barr MJ. Angiotensin-converting enzyme inhibitor fetopathy. J Am Soc Nephrology 1993;3:1575-82.
33. DiBianco R. Adverse reactions with angiotensin-converting enzyme inhibitors. Med Toxicol 1986;1:122-41.